

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1226754
<b>Application Number:</b>	10599473
<b>Confirmation Number:</b>	9511
<b>Title of Invention:</b>	Alpha Aryl or Heteroaryl Methyl Beta Piperidino Propanamide Compounds as ORL1-Receptor Antagonist
<b>First Named Inventor:</b>	Yoshinobu HASHIZUME
<b>Customer Number:</b>	28880
<b>Filer:</b>	David Robert Kurlandsky/Linda Zerby
<b>Filer Authorized By:</b>	David Robert Kurlandsky
<b>Attorney Docket Number:</b>	PC32213A
<b>Receipt Date:</b>	29-SEP-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	11:44:53
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	PCT/IB05/00751

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 2360
RAM confirmation Number	170
Deposit Account	230455
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Transmittal letter	PC32213ATransmittal.pdf	187649	no	3
<b>Warnings:</b>					
<b>Information:</b>					
2	Documents submitted with 371 Applications	PC32213WO05092858A2.pdf	12649269	no	272
<b>Warnings:</b>					
<b>Information:</b>					
3	Oath or Declaration filed	PC32213ADeclaration.pdf	164129	no	2
<b>Warnings:</b>					
<b>Information:</b>					
4	Information Disclosure Statement (IDS) Filed	PC32213AIDS.pdf	167844	no	2
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	Foreign Reference	WO1994029309.pdf	7153212	no	227
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO1998025605.pdf	10500715	no	297
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	WO2002085354.pdf	2602208	no	55
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	WO2003000677.pdf	10160033	no	196
<b>Warnings:</b>					
<b>Information:</b>					

9	Foreign Reference	WO2003064425.pdf	5203575	no	100
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	JP2002173485EquivWO200226714.pdf	3995855	no	49
<b>Warnings:</b>					
<b>Information:</b>					
11	Foreign Reference	WO2002026714.pdf	4817619	no	112
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	CaloBritishJPharm.pdf	360454	no	23
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	MeunierNature.pdf	849101	no	4
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Reinscheidetal.pdf	2760571	no	3
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	RonzoniExpertOpionTherap Patents.pdf	2465674	no	22
<b>Warnings:</b>					
<b>Information:</b>					
16		PC32213APrelimAmend.pdf	401190	yes	11
	<b>Multipart Description</b>				
	<b>Doc Desc</b>		<b>Start</b>	<b>End</b>	
	Preliminary Amendment		1	1	
	Specification		2	2	

	Claims		3	10
	Applicant Arguments/Remarks Made in an Amendment		11	11
<b>Warnings:</b>				
<b>Information:</b>				
17	Application Data Sheet	PC32213AAppDataSheet.pdf	71868	no 3
<b>Warnings:</b>				
<b>Information:</b>				
This is not an USPTO supplied ADS fillable form				
18	Power of Attorney	PC32213APOA.pdf	482309	no 6
<b>Warnings:</b>				
<b>Information:</b>				
19	NPL Documents	SchmidtSocNeurosci.pdf	178881	no 1
<b>Warnings:</b>				
<b>Information:</b>				
20		PC32213APCTSpec.pdf	8595806	yes 272
	<b>Multipart Description</b>			
	<b>Doc Desc</b>	<b>Start</b>	<b>End</b>	
	Specification	1	263	
	Claims	264	271	
	Abstract	272	272	
<b>Warnings:</b>				
<b>Information:</b>				
21	Fee Worksheet (PTO-875)	fee-info.pdf	8632	no 2
<b>Warnings:</b>				
<b>Information:</b>				
<b>Total Files Size (in bytes):</b>			73776594	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.